Comparative Pharmacology
Head-to-head clinical analysis: CORTIFOAM versus YUTIQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTIFOAM versus YUTIQ.
CORTIFOAM vs YUTIQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
YUTIQ (fluocinolone acetonide intravitreal implant) is a corticosteroid that binds to glucocorticoid receptors, leading to inhibition of phospholipase A2, suppression of arachidonic acid release, and downregulation of pro-inflammatory mediators such as prostaglandins, leukotrienes, and cytokines. This reduces inflammation and vascular permeability in the eye.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
0.18 mg fluocinolone acetonide intravitreal implant (single administration) releasing 0.2 mcg/day over 36 months.
None Documented
None Documented
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
Approximately 36 months (3 years) from the intravitreal implant; reflects sustained release from the non-biodegradable implant matrix.
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Primarily hepatic/biliary; fecal excretion is the major route. Renal excretion of fluocinolone acetonide and metabolites accounts for <10%.
Category C
Category C
Corticosteroid
Corticosteroid